Gosset Allosteric Bioscience General Information
Allosteric Bioscience is a preclinical-stage biotech company leveraging quantum computing and artificial intelligence to identify novel drug targets and modulators for aging, longevity, and age-related diseases. The company has entered into research collaborations with Johns Hopkins University for fundamental work on aging mechanisms, including progeria, and has licensed technology for the treatment/prevention of sarcopenia. No clinical results have been reported as of May 2025[1][4][5].
Contact Information
United States
Drug Pipeline
Key Partnerships
Polaris Quantum Biotech (“Polarisqb”) – joint program using quantum computing/AI for drug discovery targeting aging/longevity; equity investment by Allosteric in Polarisqb[3][6][8]., Johns Hopkins University – sponsored research agreement on fundamental cell/molecular processes of health/disease/longevity; licensing agreement for sarcopenia technology[4][5].
Allosteric Bioscience Funding
No funding data available